{"id":{"repo_id":"edinburgh","oai_identifier":"oai:era.ed.ac.uk:1842/44167"},"canonical_url":"https://search.ndltd.org/etd/edinburgh/oai:era.ed.ac.uk:1842/44167","repository":{"repo_id":"edinburgh","name":"University of Edinburgh","base_url":"https://era.ed.ac.uk/server/oai/request"},"display":{"title":"Genetic basis of previously unexplained aniridia","abstract":"Classical aniridia [MIM 106210] is a rare, panocular malformation characterised by a spectrum of iris and foveal hypoplasia, later complicated by cataracts, lens subluxation, glaucoma and keratopathy. It is overwhelmingly associated with PAX6 [MIM 607108] haploinsufficiency. PAX6 is a highly-conserved transcription factor that orchestrates eye development. Whilst the molecular genetic basis of aniridia and PAX6 disruption is broadly known, there remain unexplained areas that have guided the work in this thesis. PAX6 missense variants can partially or fully phenocopy haploinsufficiency, causing classical aniridia. Why they also cause rare “worse than null” phenotypes is unclear. In order to study the effect of variant class on phenotype, I performed systematic, detailed ocular phenotyping followed by cluster analysis of PAX6 eye malformations. This compared all available missense variant cases (n=161) with a size-matched control of likely gene-disruptive (LGD) cases. Whilst LGD variants were almost universally associated with classical aniridia, the phenotypic spectrum of missense cases was wider and appeared to cluster separately, ranging in severity from isolated foveal hypoplasia (hypomorphic) to bilateral severe microphthalmia (worse than null). Recurrent substitutions of key residues in the DNA-binding paired domain of PAX6 accounted for the most severe cases, notably p.Ser54Arg and p.Asn124Lys. The impact of these variants was investigated in vitro, studying the binding of purified PAX6 paired domain to well-characterised PAX6 DNA targets, the LE9 and SIMO enhancers. Electromobility shift assays showed that binding was altered by p.Ser54Arg and p.Asn124Lys compared to wild type, though (unlike classical aniridia variants) not totally abrogated. Their impact differed between the two DNA targets studied. Whilst not explaining all of the observed genotype-phenotype correlation, these data suggest that the variants do alter protein-DNA interactions - consistent with results of protein modelling - and could affect the stoichiometry of PAX6 target gene activation. I noted a striking similarity between the rare, severe PAX6 missense cases above and those seen in six families with heterozygous variants in MAB21L1 [MIM 601280], all resulting in Arg51 and Phe52 substitutions. All had aniridia and/or microphthalmia, 3/6 had both, and 2/6 had anomalous optic discs. MAB21L1 is involved in eye development downstream of PAX6, but was not known to cause aniridia. To characterise this further, ocular phenotyping of a CRIPSR-Cas9 gene-edited mouse strain carrying Mab21l1 p.Arg51Leu was performed. Adult mice heterozygous for this allele had a highly-penetrant excavated optic nerve anomaly. The phenotype overlaps with but is milder than the human counterpart. The homozygous animals showed severe microphthalmia. There are still questions to be answered regarding the mechanisms in both human and mouse, which may differ, but the human genetic data strongly support this being a new aniridia-associated gene with a gain of function effect. A small proportion of aniridia is still genetically uncharacterised, indicating that there could be novel ways of inactivating PAX6 or additional disease loci. To address this, I undertook analysis of 37 unrelated mutation-negative individuals with classical aniridia (n=51 including relatives) using paired-end, short-read whole genome sequencing (WGS) technology. Following an in-house analysis pipeline, causative variants were identified in 22/37 cases (60%). 15/22 were structural variants, including: chromosome 11 inversions, one separating PAX6 from its critical downstream enhancers; deletions of this downstream enhancer region; whole/partial gene deletions of PAX6, and lastly three FOXC1 gene deletions. The remainder were intragenic PAX6 single nucleotide variants, including two deep intronic splice variants. RT-PCR analysis of RNA from patient-derived lymphoblastoid cell lines was performed in a subset, confirming missplicing in vitro. Notwithstanding historical differences in PAX6 screening, it is remarkable that over half the cohort had a disease mechanism involving either PAX6 or its regulatory region, highlighting the unusually strong disease-gene link. In summary, this thesis fills gaps in our understanding of aniridia genetics through whole genome diagnosis of unsolved cases, underlining the importance of the wider PAX6 locus and adding to the known variants which inactivate it, as well as through characterisation of severe aniridia-microphthalmia phenotypes caused by rare missense variants in PAX6 and in the novel aniridia-associated gene MAB21L1.","abstract_html":"Classical aniridia [MIM 106210] is a rare, panocular malformation characterised by a spectrum of iris and foveal hypoplasia, later complicated by cataracts, lens subluxation, glaucoma and keratopathy. It is overwhelmingly associated with PAX6 [MIM 607108] haploinsufficiency. PAX6 is a highly-conserved transcription factor that orchestrates eye development. Whilst the molecular genetic basis of aniridia and PAX6 disruption is broadly known, there remain unexplained areas that have guided the work in this thesis. PAX6 missense variants can partially or fully phenocopy haploinsufficiency, causing classical aniridia. Why they also cause rare “worse than null” phenotypes is unclear. In order to study the effect of variant class on phenotype, I performed systematic, detailed ocular phenotyping followed by cluster analysis of PAX6 eye malformations. This compared all available missense variant cases (n=161) with a size-matched control of likely gene-disruptive (LGD) cases. Whilst LGD variants were almost universally associated with classical aniridia, the phenotypic spectrum of missense cases was wider and appeared to cluster separately, ranging in severity from isolated foveal hypoplasia (hypomorphic) to bilateral severe microphthalmia (worse than null). Recurrent substitutions of key residues in the DNA-binding paired domain of PAX6 accounted for the most severe cases, notably p.Ser54Arg and p.Asn124Lys. The impact of these variants was investigated in vitro, studying the binding of purified PAX6 paired domain to well-characterised PAX6 DNA targets, the LE9 and SIMO enhancers. Electromobility shift assays showed that binding was altered by p.Ser54Arg and p.Asn124Lys compared to wild type, though (unlike classical aniridia variants) not totally abrogated. Their impact differed between the two DNA targets studied. Whilst not explaining all of the observed genotype-phenotype correlation, these data suggest that the variants do alter protein-DNA interactions - consistent with results of protein modelling - and could affect the stoichiometry of PAX6 target gene activation. I noted a striking similarity between the rare, severe PAX6 missense cases above and those seen in six families with heterozygous variants in MAB21L1 [MIM 601280], all resulting in Arg51 and Phe52 substitutions. All had aniridia and/or microphthalmia, 3/6 had both, and 2/6 had anomalous optic discs. MAB21L1 is involved in eye development downstream of PAX6, but was not known to cause aniridia. To characterise this further, ocular phenotyping of a CRIPSR-Cas9 gene-edited mouse strain carrying Mab21l1 p.Arg51Leu was performed. Adult mice heterozygous for this allele had a highly-penetrant excavated optic nerve anomaly. The phenotype overlaps with but is milder than the human counterpart. The homozygous animals showed severe microphthalmia. There are still questions to be answered regarding the mechanisms in both human and mouse, which may differ, but the human genetic data strongly support this being a new aniridia-associated gene with a gain of function effect. A small proportion of aniridia is still genetically uncharacterised, indicating that there could be novel ways of inactivating PAX6 or additional disease loci. To address this, I undertook analysis of 37 unrelated mutation-negative individuals with classical aniridia (n=51 including relatives) using paired-end, short-read whole genome sequencing (WGS) technology. Following an in-house analysis pipeline, causative variants were identified in 22/37 cases (60%). 15/22 were structural variants, including: chromosome 11 inversions, one separating PAX6 from its critical downstream enhancers; deletions of this downstream enhancer region; whole/partial gene deletions of PAX6, and lastly three FOXC1 gene deletions. The remainder were intragenic PAX6 single nucleotide variants, including two deep intronic splice variants. RT-PCR analysis of RNA from patient-derived lymphoblastoid cell lines was performed in a subset, confirming missplicing in vitro. Notwithstanding historical differences in PAX6 screening, it is remarkable that over half the cohort had a disease mechanism involving either PAX6 or its regulatory region, highlighting the unusually strong disease-gene link. In summary, this thesis fills gaps in our understanding of aniridia genetics through whole genome diagnosis of unsolved cases, underlining the importance of the wider PAX6 locus and adding to the known variants which inactivate it, as well as through characterisation of severe aniridia-microphthalmia phenotypes caused by rare missense variants in PAX6 and in the novel aniridia-associated gene MAB21L1.","abstract_has_math":false,"creators":["Hall, Hildegard Nikki"],"institution":"The University of Edinburgh","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Bickmore, Wendy","Rainger, Joe"],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-11-11","date_published":"2025-11-11","updated_at":"2026-11-18T19:24:45Z","subjects":["aniridia","microphthalmia","eye malformations","rmations","whole genome sequencing"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://dx.doi.org/10.7488/era/6691"],"render_values":[{"text":"http://dx.doi.org/10.7488/era/6691","href":"http://dx.doi.org/10.7488/era/6691","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1842/44167","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/1842/44167","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://era.ed.ac.uk/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aera.ed.ac.uk%3A1842%2F44167","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Bickmore, Wendy","Rainger, Joe"]},{"key":"dc:creator","label":"Author","values":["Hall, Hildegard Nikki"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-11-11T13:16:45Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-11-11T13:16:45Z"]},{"key":"dc:date.issued","label":"Date","values":["2025-11-11"]},{"key":"dc:publisher","label":"Institution","values":["The University of Edinburgh"]},{"key":"dc:relation.hasversion","label":"Dc Relation Hasversion","values":["Hall HN, Williamson KA, FitzPatrick DR. The genetic architecture of aniridia and Gillespie syndrome. Hum Genet. 2019 Sep 1;138(8–9):881–98","Burgess FR, Hall HN, Megaw R. Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease. The Asia-Pacific Journal of Ophthalmology. 2022 Aug;11(4):380","Hall HN, Bengani H, Hufnagel RB, Damante G, Ansari M, Marsh JA, et al. Monoallelic variants resulting in substitutions of MAB21L1 Arg51 Cause Aniridia and microphthalmia. Swaroop A, editor. PLoS ONE. 2022 Nov 22;17(11):e0268149","Williamson KA, Hall HN, Owen LJ, Livesey BJ, Hanson IM, Adams GGW, et al. Recurrent heterozygous PAX6 missense variants cause severe bilateral microphthalmia via predictable effects on DNA-protein interaction. Genet Med. 2019 Nov 8;20(11):1011–2","McDonnell AF, Plech M, Livesey BJ, Gerasimavicius L, Owen LJ, Hall HN, et al. Deep mutational scanning quantifies DNA binding and predicts clinical outcomes of PAX6 variants. Mol Syst Biol. 2024 Jun 7;20(7):825–44","Hall HN, Parry D, Halachev M, Williamson KA, Donnelly K, Campos Parada J, et al. Short-read whole genome sequencing identifies causative variants in most individuals with previously unexplained aniridia. J Med Genet. 2023 Nov 30;jmg-2023-109181","Rowlands CF, Taylor A, Rice G, Whiffin N, Hall HN, Newman WG, et al. MRSD: A quantitative approach for assessing suitability of RNA-seq in the investigation of mis-splicing in Mendelian disease. The American Journal of Human Genetics. 2022 Feb;109(2):210–22","McDonnell AF, Plech M, Livesey BJ, Gerasimavicius L, Owen LJ, Hall HN, et al. Deep mutational scanning quantifies DNA binding and predicts clinical outcomes of PAX6 variants [Internet]. bioRxiv; 2023 [cited 2023 Nov 12]. p. 2023.07.25.550478. Available from: https://www.biorxiv.org/content/10.1101/2023.07.25.550478v1"]},{"key":"dc:type","label":"Dc Type","values":["Thesis or Dissertation"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Doctoral"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["PhD Doctor of Philosophy"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["aniridia","microphthalmia","eye malformations","rmations","whole genome sequencing"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1842/44167","http://dx.doi.org/10.7488/era/6691"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Classical aniridia [MIM 106210] is a rare, panocular malformation characterised by a spectrum of iris and foveal hypoplasia, later complicated by cataracts, lens subluxation, glaucoma and keratopathy. It is overwhelmingly associated with PAX6 [MIM 607108] haploinsufficiency. PAX6 is a highly-conserved transcription factor that orchestrates eye development. Whilst the molecular genetic basis of aniridia and PAX6 disruption is broadly known, there remain unexplained areas that have guided the work in this thesis. PAX6 missense variants can partially or fully phenocopy haploinsufficiency, causing classical aniridia. Why they also cause rare “worse than null” phenotypes is unclear. In order to study the effect of variant class on phenotype, I performed systematic, detailed ocular phenotyping followed by cluster analysis of PAX6 eye malformations. This compared all available missense variant cases (n=161) with a size-matched control of likely gene-disruptive (LGD) cases. Whilst LGD variants were almost universally associated with classical aniridia, the phenotypic spectrum of missense cases was wider and appeared to cluster separately, ranging in severity from isolated foveal hypoplasia (hypomorphic) to bilateral severe microphthalmia (worse than null). Recurrent substitutions of key residues in the DNA-binding paired domain of PAX6 accounted for the most severe cases, notably p.Ser54Arg and p.Asn124Lys. The impact of these variants was investigated in vitro, studying the binding of purified PAX6 paired domain to well-characterised PAX6 DNA targets, the LE9 and SIMO enhancers. Electromobility shift assays showed that binding was altered by p.Ser54Arg and p.Asn124Lys compared to wild type, though (unlike classical aniridia variants) not totally abrogated. Their impact differed between the two DNA targets studied. Whilst not explaining all of the observed genotype-phenotype correlation, these data suggest that the variants do alter protein-DNA interactions - consistent with results of protein modelling - and could affect the stoichiometry of PAX6 target gene activation. I noted a striking similarity between the rare, severe PAX6 missense cases above and those seen in six families with heterozygous variants in MAB21L1 [MIM 601280], all resulting in Arg51 and Phe52 substitutions. All had aniridia and/or microphthalmia, 3/6 had both, and 2/6 had anomalous optic discs. MAB21L1 is involved in eye development downstream of PAX6, but was not known to cause aniridia. To characterise this further, ocular phenotyping of a CRIPSR-Cas9 gene-edited mouse strain carrying Mab21l1 p.Arg51Leu was performed. Adult mice heterozygous for this allele had a highly-penetrant excavated optic nerve anomaly. The phenotype overlaps with but is milder than the human counterpart. The homozygous animals showed severe microphthalmia. There are still questions to be answered regarding the mechanisms in both human and mouse, which may differ, but the human genetic data strongly support this being a new aniridia-associated gene with a gain of function effect. A small proportion of aniridia is still genetically uncharacterised, indicating that there could be novel ways of inactivating PAX6 or additional disease loci. To address this, I undertook analysis of 37 unrelated mutation-negative individuals with classical aniridia (n=51 including relatives) using paired-end, short-read whole genome sequencing (WGS) technology. Following an in-house analysis pipeline, causative variants were identified in 22/37 cases (60%). 15/22 were structural variants, including: chromosome 11 inversions, one separating PAX6 from its critical downstream enhancers; deletions of this downstream enhancer region; whole/partial gene deletions of PAX6, and lastly three FOXC1 gene deletions. The remainder were intragenic PAX6 single nucleotide variants, including two deep intronic splice variants. RT-PCR analysis of RNA from patient-derived lymphoblastoid cell lines was performed in a subset, confirming missplicing in vitro. Notwithstanding historical differences in PAX6 screening, it is remarkable that over half the cohort had a disease mechanism involving either PAX6 or its regulatory region, highlighting the unusually strong disease-gene link. In summary, this thesis fills gaps in our understanding of aniridia genetics through whole genome diagnosis of unsolved cases, underlining the importance of the wider PAX6 locus and adding to the known variants which inactivate it, as well as through characterisation of severe aniridia-microphthalmia phenotypes caused by rare missense variants in PAX6 and in the novel aniridia-associated gene MAB21L1."]},{"key":"dc:title","label":"Title","values":["Genetic basis of previously unexplained aniridia"]},{"key":"dc:title.alternative","label":"Alternative Title","values":["The genetic basis of previously unexplained aniridia"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Bickmore, Wendy","Rainger, Joe"],"dc:creator":["Hall, Hildegard Nikki"],"dc:date.accessioned":["2025-11-11T13:16:45Z"],"dc:date.available":["2025-11-11T13:16:45Z"],"dc:date.issued":["2025-11-11"],"dc:description.abstract":["Classical aniridia [MIM 106210] is a rare, panocular malformation characterised by a spectrum of iris and foveal hypoplasia, later complicated by cataracts, lens subluxation, glaucoma and keratopathy. It is overwhelmingly associated with PAX6 [MIM 607108] haploinsufficiency. PAX6 is a highly-conserved transcription factor that orchestrates eye development. Whilst the molecular genetic basis of aniridia and PAX6 disruption is broadly known, there remain unexplained areas that have guided the work in this thesis. PAX6 missense variants can partially or fully phenocopy haploinsufficiency, causing classical aniridia. Why they also cause rare “worse than null” phenotypes is unclear. In order to study the effect of variant class on phenotype, I performed systematic, detailed ocular phenotyping followed by cluster analysis of PAX6 eye malformations. This compared all available missense variant cases (n=161) with a size-matched control of likely gene-disruptive (LGD) cases. Whilst LGD variants were almost universally associated with classical aniridia, the phenotypic spectrum of missense cases was wider and appeared to cluster separately, ranging in severity from isolated foveal hypoplasia (hypomorphic) to bilateral severe microphthalmia (worse than null). Recurrent substitutions of key residues in the DNA-binding paired domain of PAX6 accounted for the most severe cases, notably p.Ser54Arg and p.Asn124Lys. The impact of these variants was investigated in vitro, studying the binding of purified PAX6 paired domain to well-characterised PAX6 DNA targets, the LE9 and SIMO enhancers. Electromobility shift assays showed that binding was altered by p.Ser54Arg and p.Asn124Lys compared to wild type, though (unlike classical aniridia variants) not totally abrogated. Their impact differed between the two DNA targets studied. Whilst not explaining all of the observed genotype-phenotype correlation, these data suggest that the variants do alter protein-DNA interactions - consistent with results of protein modelling - and could affect the stoichiometry of PAX6 target gene activation. I noted a striking similarity between the rare, severe PAX6 missense cases above and those seen in six families with heterozygous variants in MAB21L1 [MIM 601280], all resulting in Arg51 and Phe52 substitutions. All had aniridia and/or microphthalmia, 3/6 had both, and 2/6 had anomalous optic discs. MAB21L1 is involved in eye development downstream of PAX6, but was not known to cause aniridia. To characterise this further, ocular phenotyping of a CRIPSR-Cas9 gene-edited mouse strain carrying Mab21l1 p.Arg51Leu was performed. Adult mice heterozygous for this allele had a highly-penetrant excavated optic nerve anomaly. The phenotype overlaps with but is milder than the human counterpart. The homozygous animals showed severe microphthalmia. There are still questions to be answered regarding the mechanisms in both human and mouse, which may differ, but the human genetic data strongly support this being a new aniridia-associated gene with a gain of function effect. A small proportion of aniridia is still genetically uncharacterised, indicating that there could be novel ways of inactivating PAX6 or additional disease loci. To address this, I undertook analysis of 37 unrelated mutation-negative individuals with classical aniridia (n=51 including relatives) using paired-end, short-read whole genome sequencing (WGS) technology. Following an in-house analysis pipeline, causative variants were identified in 22/37 cases (60%). 15/22 were structural variants, including: chromosome 11 inversions, one separating PAX6 from its critical downstream enhancers; deletions of this downstream enhancer region; whole/partial gene deletions of PAX6, and lastly three FOXC1 gene deletions. The remainder were intragenic PAX6 single nucleotide variants, including two deep intronic splice variants. RT-PCR analysis of RNA from patient-derived lymphoblastoid cell lines was performed in a subset, confirming missplicing in vitro. Notwithstanding historical differences in PAX6 screening, it is remarkable that over half the cohort had a disease mechanism involving either PAX6 or its regulatory region, highlighting the unusually strong disease-gene link. In summary, this thesis fills gaps in our understanding of aniridia genetics through whole genome diagnosis of unsolved cases, underlining the importance of the wider PAX6 locus and adding to the known variants which inactivate it, as well as through characterisation of severe aniridia-microphthalmia phenotypes caused by rare missense variants in PAX6 and in the novel aniridia-associated gene MAB21L1."],"dc:identifier.uri":["https://hdl.handle.net/1842/44167","http://dx.doi.org/10.7488/era/6691"],"dc:language.iso":["en"],"dc:publisher":["The University of Edinburgh"],"dc:relation.hasversion":["Hall HN, Williamson KA, FitzPatrick DR. The genetic architecture of aniridia and Gillespie syndrome. Hum Genet. 2019 Sep 1;138(8–9):881–98","Burgess FR, Hall HN, Megaw R. Emerging Gene Manipulation Strategies for the Treatment of Monogenic Eye Disease. The Asia-Pacific Journal of Ophthalmology. 2022 Aug;11(4):380","Hall HN, Bengani H, Hufnagel RB, Damante G, Ansari M, Marsh JA, et al. Monoallelic variants resulting in substitutions of MAB21L1 Arg51 Cause Aniridia and microphthalmia. Swaroop A, editor. PLoS ONE. 2022 Nov 22;17(11):e0268149","Williamson KA, Hall HN, Owen LJ, Livesey BJ, Hanson IM, Adams GGW, et al. Recurrent heterozygous PAX6 missense variants cause severe bilateral microphthalmia via predictable effects on DNA-protein interaction. Genet Med. 2019 Nov 8;20(11):1011–2","McDonnell AF, Plech M, Livesey BJ, Gerasimavicius L, Owen LJ, Hall HN, et al. Deep mutational scanning quantifies DNA binding and predicts clinical outcomes of PAX6 variants. Mol Syst Biol. 2024 Jun 7;20(7):825–44","Hall HN, Parry D, Halachev M, Williamson KA, Donnelly K, Campos Parada J, et al. Short-read whole genome sequencing identifies causative variants in most individuals with previously unexplained aniridia. J Med Genet. 2023 Nov 30;jmg-2023-109181","Rowlands CF, Taylor A, Rice G, Whiffin N, Hall HN, Newman WG, et al. MRSD: A quantitative approach for assessing suitability of RNA-seq in the investigation of mis-splicing in Mendelian disease. The American Journal of Human Genetics. 2022 Feb;109(2):210–22","McDonnell AF, Plech M, Livesey BJ, Gerasimavicius L, Owen LJ, Hall HN, et al. Deep mutational scanning quantifies DNA binding and predicts clinical outcomes of PAX6 variants [Internet]. bioRxiv; 2023 [cited 2023 Nov 12]. p. 2023.07.25.550478. Available from: https://www.biorxiv.org/content/10.1101/2023.07.25.550478v1"],"dc:subject":["aniridia","microphthalmia","eye malformations","rmations","whole genome sequencing"],"dc:title":["Genetic basis of previously unexplained aniridia"],"dc:title.alternative":["The genetic basis of previously unexplained aniridia"],"dc:type":["Thesis or Dissertation"],"dc:type.qualificationlevel":["Doctoral"],"dc:type.qualificationname":["PhD Doctor of Philosophy"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:24:45Z"}